JP2024524631A5 - - Google Patents

Info

Publication number
JP2024524631A5
JP2024524631A5 JP2024501536A JP2024501536A JP2024524631A5 JP 2024524631 A5 JP2024524631 A5 JP 2024524631A5 JP 2024501536 A JP2024501536 A JP 2024501536A JP 2024501536 A JP2024501536 A JP 2024501536A JP 2024524631 A5 JP2024524631 A5 JP 2024524631A5
Authority
JP
Japan
Prior art keywords
compound
inhibitors
interferonism
lupus erythematosus
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024501536A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024524631A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/069362 external-priority patent/WO2023285405A1/en
Publication of JP2024524631A publication Critical patent/JP2024524631A/ja
Publication of JP2024524631A5 publication Critical patent/JP2024524631A5/ja
Pending legal-status Critical Current

Links

JP2024501536A 2021-07-12 2022-07-11 炎症性疾患の治療 Pending JP2024524631A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21305971 2021-07-12
EP21305971.0 2021-07-12
EP22315039.2 2022-02-24
EP22315039 2022-02-24
PCT/EP2022/069362 WO2023285405A1 (en) 2021-07-12 2022-07-11 Treatment of inflammatory diseases

Publications (2)

Publication Number Publication Date
JP2024524631A JP2024524631A (ja) 2024-07-05
JP2024524631A5 true JP2024524631A5 (enExample) 2025-07-17

Family

ID=82748704

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024501536A Pending JP2024524631A (ja) 2021-07-12 2022-07-11 炎症性疾患の治療

Country Status (9)

Country Link
US (1) US20240325404A1 (enExample)
EP (1) EP4370128A1 (enExample)
JP (1) JP2024524631A (enExample)
KR (1) KR20240035480A (enExample)
AU (1) AU2022310901A1 (enExample)
CA (1) CA3225221A1 (enExample)
IL (1) IL309946A (enExample)
MX (1) MX2024000517A (enExample)
WO (1) WO2023285405A1 (enExample)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201717260D0 (en) * 2017-10-20 2017-12-06 Galapagos Nv Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders

Similar Documents

Publication Publication Date Title
JP2022009090A5 (enExample)
JP6837700B2 (ja) ジピベフリンの使用方法
JP5769762B2 (ja) 治療組成物およびその使用
JP2023065622A (ja) 重度腎機能障害を有する癌患者に対する治療方法
JP6574415B2 (ja) アタザナビルおよびコビシスタットのhiv治療製剤
JP5362151B2 (ja) Pgd2拮抗剤及びヒスタミン拮抗剤からなるアレルギー性鼻炎治療用医薬
WO2005004915A2 (en) Compositions comprising meloxicam
US20230115867A1 (en) Pemafibrate Dosing Regimens
JP2006511538A (ja) 非ヌクレオシド系逆転写酵素阻害剤(nnrti)とプロテアーゼ阻害剤などのシトクロムp450の阻害剤とを含む組み合わせの使用
JP6181044B2 (ja) カプセル剤
JP2021503457A (ja) 二元的なmekシグナル伝達の低減によるがん治療
EP4196116B1 (en) Pharmaceutical composition comprising cabozantinib, plerixafor, afatinib and etoricoxib for use in the treatment or prophylaxis of nsclc without driver mutations
BR112021012255A2 (pt) Método para o tratamento de um câncer em um paciente, método para reduzir efeitos colaterais do tratamento de um câncer em um paciente, combinação de um inibidor de cyp3a e docetaxel para uso em um tratamento médico de um câncer, docetaxel para uso em uma terapia de combinação no tratamento de câncer, inibidor de cyp3a para uso em uma terapia de combinação no tratamento de câncer, uso e kit que compreende uma composição farmacêutica para administração oral que compreende docetaxel e uma composição farmacêutica que compreende um inibidor de cyp3a
CN115778956A (zh) 用于治疗癌症的口服给药紫杉醇和P-gp抑制剂的治疗组合
GB2597635A (en) Combinations
EP1667719B1 (en) Treatment of gastrointestinal stromal tumors with imatinib and midostaurin
RU2842683C1 (ru) Фармацевтическая комбинация осельтамивира, парацетамола, источника витамина с и блокатора гистаминовых рецепторов
Tablets Full Prescribing Information
RU2234922C2 (ru) Антигриппозный комплексный препарат
WO2025265030A1 (en) Concomitant administration of selective glucocorticoid receptor modulator relacorilant and p-glycoprotein substrates
US20140322320A1 (en) Novel compositions for emesis control in cancer patients undergoing chemotherapy and methods thereof
RU2543322C1 (ru) Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
EP4114366A1 (en) Pharmaceutical compositions comprising dasatinib anhydrous and uses thereof